16 Jul Working Toward a Common Goal: CAM2038 PDUFA
At Braeburn, we foster a team-oriented culture. Over the past few months, we have been working on the resubmission of our NDA for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly subcutaneous depot injection for the treatment of adults with opioid use disorder (OUD). We are thrilled to have received our FDA assigned PDUFA date of December 26, 2018 for the CAM2038 NDA, which was previously granted Fast Track and Priority Review designations.
This submission exemplifies the collaboration and dedication of Team Braeburn who worked seamlessly together to support our mission: to help end the opioid addiction epidemic.
It’s amazing what can be accomplished when top performing people come together with one focus. This focus will drive us forward as we continue to work to improve the lives of patients living with opioid use disorder.